INS and hyperinsulinism: Treatment with CNX-010-49 reduced hyperinsulinemia (both fasting and fed plasma insulin levels) and improved peripheral insulin sensitivity as evident from improved insulin tolerance test which was further supported by reduced glucose intolerance.